You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥(600196.SH):聘任Aimin Hui為公司執行總裁
格隆匯 03-05 18:18

格隆匯 3 月 5日丨復星醫藥(600196.SH)公佈,公司第屆董事會三十次會議(臨時會議)召開,審議通過關於聘任高級管理人員的議案。

經首席執行官提名,同意聘任Aimin Hui公司執行總裁,聘任李勝利、馮蓉麗公司高級副總裁,聘任Lihui Zou公司副總裁。上述人員任期均自202135日起至本屆董事會任期屆滿之日止。

Aimin Hui196211月出生,於201711月加入集團201711月至20213月任公司高級副總裁20213月起任公司執行總裁。加入集團前,Aimin Hui19849月至19903月任河北醫科大學第四醫院醫師,19904月至19913月任日本國立癌中心醫院研修生,19914月至19949月任日本信州大學醫學院博士研究生,19941019979月任日本國立癌中心/日本科學技術廳特別研究員,199710月至200010月任東京大學醫學院文部教官助理教授、講師,200010月至200612月任美國國立癌研究所訪問科學家、研究員,20071月至200812月任GE醫療集團醫學總監,20091月至20104月任Cephalon, Inc.醫學總監,20104月至201511月曆任武田藥品工業株式會社臨牀腫瘤學總監、高級總監,201511月至201710月任賽諾菲全球臨牀研發副總裁。

Aimin Hui現任香港聯交所上市公司上海復宏漢霖生物技術股份有限公司(股份代號:02696)非執行董事。Aimin Hui19848月獲河北醫科大學醫學學士學位,於19949月獲日本信州大學醫學院博士學位。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account